Skip to main content
. 2017 Jul 4;18:134. doi: 10.1186/s12931-017-0617-7

Table 1.

Response to BT treatment, n = 24

Baseline 6 months post p
ACQ-5 3.3 ± 1.1 1.5 ± 1.1 <0.001a
FEV1%predicted 61.8 ± 15.9 68.7 ± 15.6 <0.05a
Salbutamol puffs/day 8 (11) 2 (2) <0.001b
Exacerbations/6months 2.0 (2.75) 0 (1) <0.001b
PNL mg/d n = 12 10 (7.5) 0 (4.5) <0.005b

mean ± SD, median (IQR), PNL prednisolone, apaired t test, b Wilcoxon signed rank test